Total submissions: 8
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000545540 | SCV000623109 | uncertain significance | Gorlin syndrome; Medulloblastoma | 2025-01-15 | criteria provided, single submitter | clinical testing | This sequence change replaces lysine, which is basic and polar, with arginine, which is basic and polar, at codon 460 of the SUFU protein (p.Lys460Arg). This variant is present in population databases (rs778125780, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with SUFU-related conditions. ClinVar contains an entry for this variant (Variation ID: 453960). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is not expected to disrupt SUFU protein function with a negative predictive value of 80%. Experimental studies have shown that this missense change affects SUFU function (PMID: 29654263). RNA analysis performed to evaluate the impact of this missense change on mRNA splicing indicates it does not significantly alter splicing (internal data). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Ambry Genetics | RCV000561960 | SCV000675281 | benign | Hereditary cancer-predisposing syndrome | 2023-08-29 | criteria provided, single submitter | clinical testing | This alteration is classified as benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. |
Fulgent Genetics, |
RCV000763644 | SCV000894515 | uncertain significance | Gorlin syndrome; Medulloblastoma; Familial meningioma; Joubert syndrome 32 | 2018-10-31 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV001294222 | SCV001483069 | uncertain significance | Gorlin syndrome | 2018-12-17 | criteria provided, single submitter | clinical testing | This variant was determined to be of uncertain significance according to ACMG Guidelines, 2015 [PMID:25741868]. |
Sema4, |
RCV000561960 | SCV002527193 | uncertain significance | Hereditary cancer-predisposing syndrome | 2022-02-27 | criteria provided, single submitter | curation | |
St. |
RCV001294222 | SCV002584632 | uncertain significance | Gorlin syndrome | 2022-09-09 | criteria provided, single submitter | clinical testing | The SUFU c.1379A>G (p.Lys460Arg) missense change has a maximum subpopulation frequency of 0.026% in gnomAD v2.1.1 (https://gnomad.broadinstitute.org/). The in silico tool REVEL predicts a benign effect on protein function. Transduction of a cell line with this variant led to an increase in Hedgehog pathway activity as compared to the wild-type, suggesting that this variant may have dominant-negative activity and can interfere with function of the wild-type protein (PMID: 29654263). To our knowledge, this variant has not been reported in individuals with nevoid basal cell carcinoma syndrome. In summary, the evidence currently available is insufficient to determine the clinical significance of this variant. It has therefore been classified as of uncertain significance. |
Revvity Omics, |
RCV003139745 | SCV003818144 | uncertain significance | not provided | 2019-05-31 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV003470694 | SCV004205681 | uncertain significance | Familial meningioma | 2024-03-29 | criteria provided, single submitter | clinical testing |